Can-Fite BioPharma Ltd.
Reinhold Cohn House
316 articles with Can-Fite BioPharma Ltd.
Dr. Pnina Fishman, will join other global thought-leaders in the field of non-alcoholic steatohepatitis (NASH) to speak at NASH Summit Europe in Frankfurt, Germany on October 22, 2018.
Namodenoson seeks to address a major unmet need for Child Pugh B patients with advanced liver cancer
Company signed a multi-million dollar development and distribution agreement for Piclidenoson and Namodenoson in China with CMS Medical and received an upfront payment of $2M
Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.
Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis
Study initiation will prompt a milestone payment from the recently signed deal with Gebro Holding
Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical
Upfront and milestone payments total up to $74.5M plus double-digit royalties
Erectile dysfunction market is estimated to reach $3.2 billion by 2022
Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer
Can-Fite BioPharma Ltd. today announced that U.S. researchers published scientific findings recommending development of anti-Liver Cancer Drugs based on a mechanism of action utilized by Namodenoson.
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson (CF102) in the treatment of advanced hepatocellular carcinoma (HCC) in patients whose disease has progressed on sorafenib therapy.
Can-Fite BioPharma Ltd. today provided an update on new pre-clinical data supporting the selection of the primary endpoint for the current ongoing Phase II study in NAFLD/NASH patients.
Company Received upfront payment of $2.2M as Part of Distribution Agreement for Piclidenoson in 3 European Countries
Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'
Can-Fite BioPharma Ltd. announced the publication of a paper entitled “Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson” in the Journal of Immunology Research, a peer-reviewed, online open access journal.
Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)
Can-Fite BioPharma Ltd. announced its poster presentation of the anti-inflammatory and anti-fibrogenic effects of Namodenosen in NAFLD/NASH animal model data at the 53rd Annual International Liver Congress of the European Association for the Study of the Liver (EASL) to be held on April 11-15, 2018 at the Paris Porte de Versailles in Paris, France.
A multi-million dollar agreement has been signed with Gebro Holdings for the distribution of Piclidenoson in 3 European Countries
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has entered into definitive agreements with institutional investors to receive gross proceeds of approximately $5 million.
Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
Can-Fite BioPharma announced today that pre-clinical studies show Namodenoson’s novel mechanism of action which entails de-regulation of 3 key signaling pathways which mediate the etiology and pathology of NAFLD/NASH and are responsible for the anti-inflammatory and anti-fibrogenic effect in the liver.
Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries
Can-Fite today announced it has received its first payment of approximately $2,200,000 from Gebro Holdings GmbH.
Can-Fite announced its near-term milestones for 2018, including events related to the rheumatoid arthritis/psoriasis drug Piclidenoson and the liver disease drug Namodenoson.
Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings
Can-Fite announced it has signed a distribution agreement with Gebro Holding GmBH to distribute Can-Fite’s lead drug candidate, Piclidenoson (CF101), for the treatment of rheumatoid arthritis and psoriasis in 3 European countries including Spain, Switzerland and Austria, upon receipt of regulatory approvals.
Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH
Jan. 3, 2018 12:00 UTC Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH Namodenoson improves steatosis, inflammation and ballooning in pre-clinical studies A Phase II study of Namodenoson is enrolling NAFLD/NASH patients PETACH TIKVA, Israel--( BUSINESS WIRE )-- Can-Fite BioPharma Lt